Intellia has reported positive results from its ongoing Phase I/II trial of NTLA-2002, a CRISPR-based gene editing therapy ...

NICE’s decisions for both drugs are not final and are pending more evidence. Credit: Art_Photo via Shutterstock. On 23 ...

ImmunityBio has announced the commencement of a Phase I trial evaluating its CD19 (t-haNK) cell therapy for the treatment of ...

The trial aimed to demonstrate a significant change in the 28-day frequency of TSC-associated seizures. Credit: Volha_R/Shutterstock. Marinus Pharmaceuticals has reported that the Phase III TrustTSC ...

Using GeneDX’s technology, the GUARDIAN study screens newborns for 255 early-onset genetic conditions. Credit: Maliutina Anna via Shutterstock. GeneDx has unveiled new findings from the GUARDIAN study ...

Germany-based Ottobock SE & Co. KGaA will hold an approximate 10% stake in Onward’s share capital following the investment.

OKYO Pharma has initiated the Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), by dosing the first ...

AngioDynamics has teamed up with the University College London Hospital (UCLH) in the UK to launch a prospective registry ...

There are currently no licensed vaccines to treat norovirus, a highly contagious virus that causes sickness and diarrhoea.

The reduction in anaemia was seen in patients with baseline haemoglobin levels less than 11g/dL. Credit: Orawan Pattarawim / Shutterstock. Repare Therapeutics has presented updated data from its Phase ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...

Over the past few days at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, US, the ...